News
Current position:Product Center > Antibodies > Anti-payload antibodies > Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]
Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]
Product info

Cat.No:GM-81146AB

Product:Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]




Cat. No. & Size

GM-81146AB-1mg         1mg

GM-81146AB-5mg         5mg

GM-81146AB-25mg       25mg

GM-81146AB-50mg       50mg

GM-81146AB-100mg     100mg

Description️

Expression System                               CHO

Aggregation                                         < 5% as determined by SEC-HPLC

Purity                                                     >95% as determined by SDS-PAGE

Drug-to-Antibody Ratio (DAR)           4

Endotoxin                                            <1 EU/mg, determined by LAL gel clotting assay

Sterility                                                  0.22 μm Filtered

Target                                                    HER2

Clone                                                     Trastuzumab emtansine,T-DM1

Alternative Names                               CD340, HER-2, HER-2/neu, ERBB2, MLN 19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2

Source / Isotype                                   Human IgG1 (KEEM),Kappa

Application                                           Negative control

Description                                           Human epidermal growth factor 2 is also known as erbB-2 and Neu; it is a member of the ErbBs or type I receptor tyrosine kinase family, which also includes the epidermal growth factor receptor 1 (EGFR or HER1), erbB-3 (HER3), and erbB-4 (HER4).  Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase.  ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy.

Formulation                                          Dulbecco's phosphate-buffered saline, pH 7.4

Storage temp.                                       Store at +4°C short term. Store at -20°C or -80°C long term, avoiding freeze/thaw cycles.

Data

GM-81146AB-1.png


/ueditor/image/20240527/1716786569695863/1346d6363406e714f3ab8aefb5e285b8.png


/ueditor/image/20240527/1716786588761001/1d45695c9cc8ecd02db22af563208f24.png

Current position:Product Center > -- > Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]
classify
Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]
Product info

Cat.No:GM-81146AB

Product:Anti-HER2-DM1 ADC(Dar4)[Trastuzumab emtansine,T-DM1]




Cat. No. & Size

GM-81146AB-1mg         1mg

GM-81146AB-5mg         5mg

GM-81146AB-25mg       25mg

GM-81146AB-50mg       50mg

GM-81146AB-100mg     100mg

Description️

Expression System                               CHO

Aggregation                                         < 5% as determined by SEC-HPLC

Purity                                                     >95% as determined by SDS-PAGE

Drug-to-Antibody Ratio (DAR)           4

Endotoxin                                            <1 EU/mg, determined by LAL gel clotting assay

Sterility                                                  0.22 μm Filtered

Target                                                    HER2

Clone                                                     Trastuzumab emtansine,T-DM1

Alternative Names                               CD340, HER-2, HER-2/neu, ERBB2, MLN 19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2

Source / Isotype                                   Human IgG1 (KEEM),Kappa

Application                                           Negative control

Description                                           Human epidermal growth factor 2 is also known as erbB-2 and Neu; it is a member of the ErbBs or type I receptor tyrosine kinase family, which also includes the epidermal growth factor receptor 1 (EGFR or HER1), erbB-3 (HER3), and erbB-4 (HER4).  Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase.  ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy.

Formulation                                          Dulbecco's phosphate-buffered saline, pH 7.4

Storage temp.                                       Store at +4°C short term. Store at -20°C or -80°C long term, avoiding freeze/thaw cycles.

Data

GM-81146AB-1.png


/ueditor/image/20240527/1716786569695863/1346d6363406e714f3ab8aefb5e285b8.png


/ueditor/image/20240527/1716786588761001/1d45695c9cc8ecd02db22af563208f24.png

Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit